Molecular Docking of Citronellol, Geraniol and Ester Derivatives as Pim 1 Kinase Inhibitor of Leukemia Cancer
Abstract
Keywords
References
Arsianti A, Fadilah, Kakiuchi K. 2014. Design and molecular docking study of antimycin A3 analogues as inhibitors of anti-apoptotic BCL-2 of breast cancer. Open J. of Med. Chem. 4: 79-86.
Bayala B, Bassole I, Simpore J. 2014. Anticancer activity of essential oils and their chemical components-a review. Am.J.Cancer Res. 4(6): 591-607.
Bernard S, Christopher P. 2014. WHO: World Cancer Report. IARC Nonserial Publication. 630. WHO Press.
Biblap B, Jhinuk C. 2013. Identification of proapoptopic, anti-inflammatory, anti-proliferative, invasive, and anti-angiogenic targets of essential oils in cardamom by dual reverse virtual screening and binding pose analysis. Asian Pacific Jounal of Cancer Prevention. 14: 3735-3742.
Can BKH, Buchbauer G. 2010. Handbook of Essensial Oil. 56. Printed in the United States of America on acid-free paper.
Cavar S, Maksimovic M. 2012. Antioxidant activity of essensial oil from Palmarosa (Cymbapogon martini). Food Control. 23: 263-267.
Chen W, Viljoen A. 2010. Geraniol-a review of commercial important fragance material. South African J of Botany. 76(4): 643-651.
Christodoulu M, Kontos C, Halabalaki M. 2013. Nature promises new anticancer agents : interplay with the apoptosis-related BCL2 gene family. Anticancer Agent Med.Chem. 13: 1-25.
Cragg GM, Newman DJ. 2013. Natural products as sources of new drug over the last 25 years. J. Nat. Prod. 70: 461-77.
Dykes DJ, Waud WR. 2008. Tumor Models in Cancer Research. 23-40, Humana Press, Totowa, NJ.
Fauser J. 2014. Fatty acids: novel bioactive anti-cancer therapeutics. Anticancer Agent Med.Chem.. 14: 49-65.
Ganjewala D. 2009. Cymbopogon essential oils: chemical compositions and bioactivities. J. Of Essential Oil Therapeutics. 3: 56-65.
Garcia PD, Langowski JL, Wang Y. 2014. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. Clinical Cancer Research. 30(7): 1834-1845.
Gisele AN, Matthew TB, Wooseok H. 2016. Design, synthesis and structure activity relationship of potent pan-PIM kinase inhibitors derived from the pyridyl carboxamide scaffold. Biorg. Med. Chem. Lett. 26: 2328-2332.
Grassow M, Aparicio C, Carnero A. 2014. The Pim family of Serine/Threonine Kinases in cancer, Med. Research Reviews. 34(1): 136–159.
Hannahan D, Weinberg R. 2010. Lipophilicity in drug discovery. Expert Opin. Drug Disc. 5: 235-248
Khan AQ, Khan R, Qamar W. 2013. Geraniol attenuate12-O-tetradecanoylphorbol-13-acetate (TPA) induced oxidative stress and inflammation in mouse skin: possible role of p38 MAP kinase and NF-xB. Experimental and MolecularPathology. 94(3): 419-429.
Kumar A, Malik F, Bhushan S. 2008. An essential oil and the mayor constituent isointermediol induce apoptosis by increaced expression of mitochondrial cytochrome c and epical death receptors in human leukaemia HL60 cells. Chem.Biol.Interact. 171: 332-347.
Kusumaningrum S, Budianto E, Kosela S, Sumaryono W, Juniarti F. 2014. The molecular docking of 1,4-naphthoquinone derivatives as inhibitors of Polo-like kinase 1 using Molegro Virtual Docker. J.Appl.Pharmaceutic.Scie. 4(11): 47-53.
Li Q, Cheng T, Wang Y. 2011. Drug discovery today. Pub. Chem. Drug Disc. 15(23): 1052-1057.
Lipinski CA, Lombardo F, Dominy BW. 1997. Experimental and computional approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews. 23. 3-25.
Madnooni M, Mansour K, Gholivand M. 2012. Chemical composition, cytotoxicity and antioxidant activities of the essential oil from the leaves of Citrus aurantium L. African J Biotech.11(2): 498-503.
Mandal S, Bandyopadhyay S, Ghosh MK. 2012. Natural products: promising resources for cancer drug discover. Anticancer Agent Med.Chem. 12: 49-75.
Matthew TB, Gisele N, Wooseok H. 2015. Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-ifluorophenyl)-5-fluoropicolinamide (PIM447), a potent and selective proviral insertion site of Moloney Murine Leukemia (PIM) 1, 2, and 3 kinase inhibitor in clinical trials for hematological malignancies. J. Med.Chem. 58: 8373-8378.
Merkel AL, Meggers E, Ocke M. 2012. Pim1 kinase as a target for cance. Early Online Expert Opin. Investig. Drugs. 1-12.
Narayanan A, Baskaran SA, Amalaradjon M. 2015. Anticarcinogenic properties of medium chain fatty acids on human colonrectal, skin, and breast cancer cells in vitro. Int. J. Mol. Sci. 16: 5014-5027.
Qurishi Y, Hamid A, Majeed R. 2011. Interaction of natural products with cell survival and signaling pathways in the biochemical elucidation of drug targets in cancer. Future Oncol. 7( 8): 1007-1021.
Raut JS, Karuppayil SM. 2014. A Status review on the medicinal properties of essential oil. Ind. Crops. Prod. 62: 250-264.
Ravi S, Sureshkumar C and Dhivya S. 2012. Design, synthesis, and evaluation of Geraniol esters against the inflammation drug target protein TNF-. Int. J. of Curr. Res. 4(9): 40-44.
Sharma P, Mondhe D, Muthiah S. 2009. Anticancer activity of an essential oil from Cymbopogan flexuosus. Chem. Biol. Interact. 179. 2(3): 160-168.
Siswandono. 2015. Rancangan Obat Rasional dan Pemodelan Molekul, Kuliah Umum Kimia Medisinal. 1-62, Labtiap BPPT, Puspiptek Serpong.
Tursynbay Y, Zhang J, Li Z. 2016. Pim-1 kinase as cancer drug target: an update Review. Biomed. Report. 4: 140-146.
Weirauch U, Beckmann N, Thomas M. 2013. Functional Role and Therapeutic Potential of The Pim1 Kinase in Colon Carcinoma. Neoplasia. 15 (7): 783-794.
Widiyarti G, Hanafi M, Kosela S, Budianto E. 2016. Cytotoxic activity of cytronellyl caproate on Murine Leukemia (P388) Cells. Int. J. App. Chem. 12(3): 209-220.
Yanuar A. 2012. Penambatan Molekul, Praktek dan Aplikasi pada Virtual Screening. Fakultas Farmasi Universitas Indonesia.
DOI: 10.15408/jkv.v5i2.7195
Refbacks
- There are currently no refbacks.
Copyright (c) 2019 Galuh Widiyarti
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.